Utility of computed tomography and magnetic resonance imaging staging before completion lymphadenectomy in patients with sentinel lymph node-positive melanoma

Journal of Clinical Oncology

Volumn 24, Issue 18, 2006, Pages 2858-2865

  Aloia, Thomas A ^a   Gershenwald, Jeffrey E ^a   Andtbacka, Robert H ^a   Johnson, Marcella M ^a   Schacherer, Christopher W ^a   Ng, Chaan S ^a   Cormier, Janice N ^a   Lee, Jeffrey E ^a   Ross, Merrick I ^a   Mansfield, Paul F ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC IMAGING; FEMALE; HUMAN; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; MELANOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGNOSIS; SCHOOL CHILD; SENTINEL LYMPH NODE; CHILD; METASTASIS; METHODOLOGY; MIDDLE AGED; PATHOLOGY; SENTINEL LYMPH NODE BIOPSY; SKIN TUMOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; FEMALE; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MAGNETIC RESONANCE IMAGING; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33745579977     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.05.6176     Document Type: Article

References (35)

1. Jemal A, Murray T, Ward E, et al: Cancer statistics, 2005. CA Cancer J Clin 55:10-30, 2005
2. Gershenwald J, Thompson W, Mansfield P, et al: Multi-institutional melanoma lymphatic mapping experience: The prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 17:976-983, 1999
3. Balch C, Soong S, Gershenwald J, et al: Prognostic factor analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19:3622-3634, 2001
4. Clary B, Brady M, Lewis J, et al: Sentinel lymph node biopsy in the management of patients with primary cutaneous melanoma: Review of a large single-institutional experience with an emphasis on recurrence. Ann Surg 233:250-258, 2001
5. Dessureault S, Soong S, Ross M, et al: Improved staging of node-negative patients with intermediate to thick melanomas (>1 mm) with the use of lymphatic mapping and sentinel lymph node biopsy. Ann Surg Oncol 8:766-770, 2001
6. Thompson J: The Sydney Melanoma Unit experience of sentinel lymphadenectomy for melanoma. Ann Surg Oncol 8:44S-47S, 2001 (suppl 9)
7. Morton DL, Wen DR, Wong JH, et al: Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 127:392-399, 1992
8. Gershenwald JE, Colome MI, Lee JE, et al: Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol 16:2253-2260, 1998
9. Zartman G, Thomas M, Robinson W: Metastatic disease in patients with newly diagnosed malignant melanoma. J Surg Oncol 35:163-164, 1987
10. Ardizzoni A, Grimaldi A, Repetto L, et al: Stage I-II melanoma: The value of metastatic work-up. Oncology 44:87-89, 1987
11. Buzaid A, Sandler A, Mani S, et al: Role of computed tomography in the staging of primary melanoma. J Clin Oncol 11:638-643, 1993
12. Huang C, Provost N, Marghoob A, et al: Laboratory tests and imaging studies in patients with cutaneous malignant melanoma. J Am Acad Dermatol 39:451-463, 1998
13. Kersey P, Iscoe N, Gapski J, et al: The value of staging and serial follow-up investigations in patients with completely resected, primary, cutaneous malignant melanoma. Br J Surg 72:614-617, 1985
14. Terhune M, Swanson N, Johnson T: Use of chest radiography in the initial evaluation of patients with localized melanoma. Arch Dermatol 134:569-572, 1998
15. Buzaid AC, Tinoco L, Ross MI, et al: Role of computed tomography in the staging of patients with local-regional metastases of melanoma. J Clin Oncol 13:2104-2108, 1995
16. Balch C, Soong S, Ross M, et al: Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm): Intergroup Melanoma Surgical Trial. Ann Surg Oncol 7:87-97, 2000
17. Miranda EP, Gertner M, Wall J, et al: Routine imaging of asymptomatic melanoma patients with metastasis to sentinel lymph nodes rarely identifies systemic disease. Arch Surg 139:831-836, 2004
18. Friedman K, Wahl R: Clinical use of positron emission tomography in the management of cutaneous melanoma. Semin Nucl Med 34:242-253, 2004
19. Rinne D, Baum RP, Hor G, et al: Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: Results of a prospective study of 100 patients. Cancer 82:1664-1671, 1998
20. Gritters LS, Francis IR, Zasadny KR, et al: Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose in the imaging of malignant melanoma. J Nucl Med 34: 1420-1427, 1993
21. Steinert HC, Huch Boni RA, Buck A, et al: Malignant melanoma: Staging with whole-body positron emission tomography and 2-[F-18]-fluoro-2-deoxy-D- glucose. Radiology 195:705-709, 1995
22. Swetter SM, Carroll LA, Johnson DL, et al: Positron emission tomography is superior to computed tomography for metastatic detection in melanoma patients. Ann Surg Oncol 9:646-653, 2002
23. Gulec SA, Faries MB, Lee CC, et al: The role of fluorine-18 deoxyglucose positron emission tomography in the management of patients with metastatic melanoma: Impact on surgical decision making. Clin Nucl Med 28:961-965, 2003
24. Dietlein M, Krug B, Groth W, et al: Positron emission tomography using 18F-fluorodeoxyglucose in advanced stages of malignant melanoma: A comparison of ultrasonographic and radiological methods of diagnosis. Nucl Med Commun 20:255-261, 1999
25. Tyler DS, Onaitis M, Kherani A, et al: Positron emission tomography scanning in malignant melanoma. Cancer 89:1019-1025, 2000
26. Holder WD Jr, White RL Jr, Zuger JH, et al: Effectiveness of positron emission tomography for the detection of melanoma metastases. Ann Surg 227:764-769, 1998
27. Eigtved A, Andersson AP, Dahlstrom K, et al: Use of fluorine-18 fluorodeoxyglucose positron emission tomography in the detection of silent metastases from malignant melanoma. Eur J Nucl Med 27:70-75, 2000
28. Wagner JD, Schauwecker DS, Davidson D, et al: FDG-PET sensitivity for melanoma lymph node metastases is dependent on tumor volume. J Surg Oncol 77:237-242, 2001
29. Schafer A, Herbst R, Beiteke U: Sentinel lymph node excision (SLNE) and positron emission tomography in the staging of stage I-II melanoma patients. Hautarzt 54:440-447, 2003
30. Mijnhout G, Hoekstra O, van Lingen A: How morphometry analysis of metastatic load predicts the (un)usefulness of PET scanning: The case of lymph node staging in melanoma. J Clin Pathol 56:283-286, 2003
31. Longo M, Lazaro P, Bueno C, et al: Fluorodeoxyglucose-positron emission tomography imaging versus sentinel node biopsy in the primary staging of melanoma patients. Dermatol Surg 29: 245-248, 2003
32. Hafner J, Schmid MH, Kempf W, et al: Baseline staging in cutaneous malignant melanoma. Br J Dermatol 150:677-686, 2004
33. Havenga K, Cobben DC, Oyen WJ, et al: Fluorodeoxyglucose-positron emission tomography and sentinel lymph node biopsy in staging primary cutaneous melanoma. Eur J Surg Oncol 29:662-664, 2003
34. Gershenwald J, Prieto V, Johnson M, et al: Microscopic tumor burden in sentinel lymph nodes best predicts nonsentinel lymph node involvement in patients with melanoma. 57th Annual Meeting of the Society of Surgical Oncology, Denver, CO, March 14-17, 2002
35. Gershenwald J, Prieto V, Johnson M, et al: Heterogeneity of microscopic stage III melanoma in the SLN era: Implications for AJCC/UICC staging and future clinical trial design. 6th World Congress on Melanoma, Vancouver, Canada, September 1-5, 2005